NEW YORK, May 1, 2012 /PRNewswire/ -- The results from Dr. Gilbert G. Donders' MD, PhD study testing Cutaneous Lysate in women suffering from vulvar pain has been accepted for publication in the Journal of Lower Genital Tract Disease. The journal is expected to publish the study later this year.
Cutaneous Lysate is a novel ingredient contained in NeoGyn® Vulvar Soothing Cream which is a cosmetic cream to help soothe and calm the vulvar skin and is currently marketed by Neogyn Inc., Troy, MI.
The study was conducted by Dr. Donders in 2010 and was designed to evaluate the effectiveness of Cutaneous Lysate in the treatment of provoked vestibulodynia; a form of a vulvar pain condition called vulvodynia. Provoked vestibulodynia (formally known as vulvar vestibulitis) is characterized as a local, severe, sharp pain occurring in response to touch or pressure.
The study consisted of 30 patients who experienced pain during examination and intercourse. The patients were given either a placebo or a cream with the Cutaneous Lysate to apply twice daily. The patients were tested over a three-month period with a one-week wash out phase, followed by another three months of cross-over use.
The study concluded that the use of Cutaneous Lysate was effective in reducing pain during intercourse in patients suffering from provoked vestibulodynia. In the first 12 weeks of use, those using Cutaneous Lysate showed a significant reduction of pain during sexual activity whereas those using the placebo did not. The study also indicates that those subjects who acquired vestibulodynia seem more responsive to the treatment.
"Cutaneous Lysate was effective in reducing pain while having intercourse as well as decreasing redness in patients with provoked vulvodynia, making it a promising future new therapy for those suffering with vulvar pain," says Dr. Donders.
To see more result from Dr. Donders' study, please visit www.vulvodyniatreatment.com.